Alnylam Pharmace. buy Commando
Start price
20.08.22
/
50%
€214.90
Target price
20.08.23
-
Performance (%)
-14.30%
End price
07.03.23
€184.16
Summary
This prediction ended on 07.03.23 with a price of €184.16. The prediction for Alnylam Pharmace. disappointed with a performance of -14.30%. Commando has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 5.231% | 5.231% | 16.743% | 51.070% |
| iShares Core DAX® | 0,61 % | 0,34 % | 12,06 % | 58,10 % |
| iShares Nasdaq 100 | 0,64 % | -3,17 % | 1,74 % | 84,36 % |
| iShares Nikkei 225® | -0,13 % | 8,92 % | 27,39 % | 64,84 % |
| iShares S&P 500 | 0,54 % | -0,70 % | 1,91 % | 58,67 % |
Comments by Commando for this prediction
In the thread Alnylam Pharmace. diskutieren
Buy Alnylam Pharmace.